{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:01:38Z","timestamp":1792544498541,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jaad.2013.09.044","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T02:16:23Z","timestamp":1386123383000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["An open-label study of anakinra for the treatment of\u00a0moderate to severe hidradenitis suppurativa"],"prefix":"10.1016","volume":"70","author":[{"given":"Kieron S.","family":"Leslie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani V.","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.09.044_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1468-3083.2012.04468.x","article-title":"Depression in patients with hidradenitis suppurativa","volume":"27","author":"Onderdijk","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.09.044_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","article-title":"Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States","volume":"68","author":"Cosmatos","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions","volume":"35","author":"Jemec","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib4","first-page":"1292","article-title":"Elevated levels of tumor necrosis factor\u00a0(TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br\u00a0J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study\u00a0of the safety and efficacy of etanercept for the therapy\u00a0of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib9","first-page":"501","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2013.09.044_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.09.044_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.09.044_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et\u2019s disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2013.09.044_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","article-title":"Familial autoinflammatory diseases: genetics, pathogenesis and treatment","volume":"17","author":"Stojanov","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/archderm.142.12.1591","article-title":"Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1\/NALP3 mutations","volume":"142","author":"Leslie","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/ard.2010.143438","article-title":"Favorable and sustained response to anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis","volume":"70","author":"Obici","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2013.09.044_bib19","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/ndt\/gfr528","article-title":"Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure","volume":"27","author":"Stankovic Stojanovic","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaad.2013.09.044_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of\u00a0tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"Van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.09.044_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/AJP.0b013e3181ceb80c","article-title":"Painful hidradenitis suppurativa","volume":"26","author":"Smith","year":"2010","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jaad.2013.09.044_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis suppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.09.044_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaad.2011.10.024","article-title":"Profound disturbances of sexual health in patients with acne inversa","volume":"67","author":"Kurek","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2013.09.044_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","article-title":"A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa","volume":"49","author":"Amano","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-term efficacy of a single course of infliximab in hidradenitis suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamadermatol.2013.2705","article-title":"Neutrophilic urticaria with systemic inflammation: a case series","volume":"149","author":"Belani","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2013.09.044_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human\u00a0interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2013.09.044_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with\u00a0rheumatoid arthritis treated with biologic therapy: a\u00a0meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2013.09.044_bib32","first-page":"89","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat\u00a0Rev Immunol"},{"key":"10.1016\/j.jaad.2013.09.044_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.2969618","article-title":"cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily","volume":"241","author":"Sims","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.jaad.2013.09.044_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cyto.2011.07.006","article-title":"IL-1 acts on T cells to enhance the magnitude of in\u00a0vivo immune responses","volume":"56","author":"Ben-Sasson","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.jaad.2013.09.044_bib35","first-page":"cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci\u00a0Signal"},{"key":"10.1016\/j.jaad.2013.09.044_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu\u00a0Rev Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213010402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213010402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:29:27Z","timestamp":1759271367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213010402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0190962213010402"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.09.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label study of anakinra for the treatment of\u00a0moderate to severe hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}